Centre for Evolution and Cancer (CEC)
@cec-icr.bsky.social
Evolution and cancer research @icrlondon.bsky.social.
Interests include:
drug resistance
pre-malignancy and early detection
epigenetics
plasticity
population genetics
microbiome
lineage tracing
biotech
Director @trevorgraham.bsky.social
Interests include:
drug resistance
pre-malignancy and early detection
epigenetics
plasticity
population genetics
microbiome
lineage tracing
biotech
Director @trevorgraham.bsky.social
Reposted by Centre for Evolution and Cancer (CEC)
Of course, the original idea of Adaptive Therapy was from the visionary Robert (Bob) Gatenby at @moffittnews.bsky.social. His seminal paper:
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
Adaptive Therapy
Abstract. A number of successful systemic therapies are available for treatment of disseminated cancers. However, tumor response is often transient, and therapy frequently fails due to emergence of re...
aacrjournals.org
May 2, 2025 at 12:58 PM
Of course, the original idea of Adaptive Therapy was from the visionary Robert (Bob) Gatenby at @moffittnews.bsky.social. His seminal paper:
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
Reposted by Centre for Evolution and Cancer (CEC)
In other words - remarkably - it could be that less drug, less often leads to better outcomes for some patients with ovarian cancer.
We eagerly await the clinical trial results - they will be definitive.
We eagerly await the clinical trial results - they will be definitive.
May 2, 2025 at 12:52 PM
In other words - remarkably - it could be that less drug, less often leads to better outcomes for some patients with ovarian cancer.
We eagerly await the clinical trial results - they will be definitive.
We eagerly await the clinical trial results - they will be definitive.
Reposted by Centre for Evolution and Cancer (CEC)
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha...
Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...
bmjopen.bmj.com
May 2, 2025 at 12:50 PM
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...
Reposted by Centre for Evolution and Cancer (CEC)
With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...
aacrjournals.org
May 2, 2025 at 12:43 PM
With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
Reposted by Centre for Evolution and Cancer (CEC)
Delighted that a major project of my post-doctoral fellowship in the de Bono lab has been published. A really interesting story, featuring the likes of @icrlordlab.bsky.social @boragurel.bsky.social among many others at @icrlondon.bsky.social and elsewhere.
This weeks coffee club paper focuses on genomic changes linked to PARP inhibitor resistance ☕
The work was led by @prostatecanceruk.bsky.social's Travel Prize Fellow @seedgeorge.bsky.social from @icrlondon.bsky.social
Congratulations to George and team 🥳
t.co/rC22HnAKIs
#prostatecancer #research
The work was led by @prostatecanceruk.bsky.social's Travel Prize Fellow @seedgeorge.bsky.social from @icrlondon.bsky.social
Congratulations to George and team 🥳
t.co/rC22HnAKIs
#prostatecancer #research
December 5, 2024 at 8:24 PM
Delighted that a major project of my post-doctoral fellowship in the de Bono lab has been published. A really interesting story, featuring the likes of @icrlordlab.bsky.social @boragurel.bsky.social among many others at @icrlondon.bsky.social and elsewhere.
Frequent evolution of BRCA2 reversion mutations during PARPi treatment in prostate cancer
From @seedgeorge.bsky.social Johann De Bono and colleagues (us !). In BRCA2m CRPC, reversion mutations emerge in 79% by end of olaparib treatment. Reversions associate with PFS and OS. Rare subclones without BRCA2-loss also emerge authors.elsevier.com/sd/article/S...
ScienceDirect.com | Science, health and medical journals, full text articles and books.
authors.elsevier.com
November 22, 2024 at 9:29 AM
Frequent evolution of BRCA2 reversion mutations during PARPi treatment in prostate cancer
Welcome to #bsky @alejandrapcelab.bsky.social ! Alejandra Bruna leads the paediatric cancer evolution (PCE) lab here in our @cec-icr.bsky.social. Focusing on dissecting the role of phenotypic plasticity in childhood cancer evolution and therapy response.
November 21, 2024 at 2:58 PM
Welcome to #bsky @alejandrapcelab.bsky.social ! Alejandra Bruna leads the paediatric cancer evolution (PCE) lab here in our @cec-icr.bsky.social. Focusing on dissecting the role of phenotypic plasticity in childhood cancer evolution and therapy response.